Purpose
Below are recent publications related to vaccines in CDC's Morbidity and Mortality Weekly Report (MMWR).
June 2025
- Rao AK, Minhaj FS, Carter RJ, Duffy J, Satheshkumar PS, Delaney KP, et al. Use of JYNNEOS (Smallpox and Mpox Vaccine, Live, Nonreplicating) for Persons Aged ≥18 Years at Risk for Mpox During an Mpox Outbreak: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 MMWR 2025. / 74(22);385–392
- In 2023, the Advisory Committee on Immunization Practices (ACIP) recommended JYNNEOS (smallpox and mpox vaccine, live, nonreplicating) for persons aged ≥18 years who are at risk for mpox...
- Mutuku P, Abade A, Owiny M, Irura Z, Roba A, Limo H et al. Clade Ib Mpox Outbreak — Kenya, July 2024–February 2025 MMWR 2025 / 74(22);379–384
- This report highlights the potential for mpox transmission on cruise ships for both passengers and crew members.
- Ortiz N, Rodriguez LR, McPherson M, Pringle K, Rao AK, Tuttle A, et al. Clade II Mpox Infections Among Cruise Ship Passengers and Crew Members — United States, 2024 MMWR 2025. / 74(22);373–378
- This report describes the characteristics of laboratory-confirmed clade Ib mpox cases in Kenya during the first 7 months of the outbreak.
May 2025
- Lebo E, Vynnycky E, Alexander Jr. JP, Ferrari MJ, Winter AK, Frey K, et al. Estimated Current and Future Congenital Rubella Syndrome Incidence with and Without Rubella Vaccine Introduction — 19 Countries, 2019–2055 MMWR 2025. / 74(18);305–311
- This report describes the estimated current and future estimated CRS incidence in the 19 countries** that had not introduced RCV by the end of 2023...
- Patton ME, Moline HL, Whitaker M, Tannis A, Pham H, Toepfer AP, et al. Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025 MMWR 2025. / 74(16);273–81
- Advisory Committee on Immunization Practices’ recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants...
April 2025
- Mathis AD, Raines K, Filardo TD, Wiley N, Leung J, Rota PA, et al. Measles Update — United States, January 1–April 17, 2025 MMWR 2025 / 74(14);232–8
- Increasing national and local measles, mumps, and rubella vaccination coverage is essential to preventing measles cases and outbreaks
February 2025
- Huseynov S, Saxentoff E, Diedrich S, Martin J, Wieczorek M, Cabrerizo M, et al. Notes from the Field: Detection of Vaccine-Derived Poliovirus Type 2 in Wastewater — Five European Countries, September–December 2024 MMWR 2025. 74(7);122–124
- This report describes detection of vaccine-derived poliovirus type 2 in Wastewater.
- Gargano JW, Stefanos R, Dahl RM, Castilho JL, Erica A. Bostick EA, Niccolai LM, et al. Trends in Cervical Precancers Identified Through Population-Based Surveillance — Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022 MMWR 2025. 74(6);96-101
- This analysis describes trends in incidence of CIN2+ and CIN3+ (i.e., CIN grade 3 and AIS) lesions during 2008–2022.
- Fazal A, Reinhart K, Huang S, Kniss K, Olson SM, Dugan VG, Ellington S, et al. Reports of Encephalopathy Among Children with Influenza-Associated Mortality — United States, 2010–11 Through 2024–25 Influenza Seasons MMWR 2025. / 74(6);91-95
- Among 1,850 flu-related deaths in children reported to CDC during the 2010–11 through 2023–24 flu seasons, a total of 166 (9%) children had influenza-associated encephalopathy or encephalitis.
- Link-Gelles R, Chickery S, Webber A, Ong TC, Rowley E A.K., DeSilva MB, et al. Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025 MMWR 2025. / 74(6);73-82
- This report provides interim estimates of effectiveness of any 2024–2025 influenza vaccine...
- Levy V, Branzuela A, Hsieh K, Getabecha S, Berumen III R, Saadeh K, et al. First Clade Ib Monkeypox Virus Infection Reported in the Americas — California, November 2024 MMWR 2025. / 74(3)44-49
- This report describes the clinical features of and public health response to the first identified clade Ib MPXV infection in the Americas.
January 2025
- Wodi AP, Issa AN, Moser CA, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2025 MMWR 2025. / 74(2);30–33
- At its October 2024 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Immunization Schedule for Adults Ages 19 Years or Older, United States, 2025...
- Issa AN, Wodi AP, Moser CA, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2025 MMWR 2025. / 74(2);26–29
- At its October 2024 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2025...
- Kobayashi M, Leidner AJ, Gierke R, Xing W, Accorsi E, Moro P, et al. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 MMWR 2025. / 74(1);1–8
- This report summarizes evidence considered for these recommendations and provides updated clinical guidance for use of PCV.